 Home > Active Ingredient News > Antitumor Therapy > ESMO Strikes Directly at the First Prospective Study: An Exploration of the Mechanism of Oshitinib Resistance

ESMO Strikes Directly at the First Prospective Study: An Exploration of the Mechanism of Oshitinib Resistance

 Last Update: 2022-10-03
 Source: Internet
 Author: User

Tags

primary cell

egfr 55

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The European Society for Internal Oncology (ESMO) Annual Meeting is the most prestigious and influential oncology conference

In the oral presentation, Professor Zofia Piotrowska presented the results of the ELIOS study, which for the first time prospectively explored the mechanism

Professor Zofia Piotrowska

background

Third-generation EGFR TKI ositinib is the preferred first-line treatment for

method

Patients with EGFR-TKI initial treatment of advanced EGFR-sensitive mutation NSCLC are treated

outcome

A total of 154 patients were included in the study (full set of analyses; FAS), median age was 62 years, 77% were Asians, and 55%, 38%, and 7%

conclusion

Only 46 paired samples with valid NGS results were collected in patients with disease progression, suggesting the challenge of
obtaining a more comprehensive, non-invasive approach to obtaining disease progression tissue biopsy samples.

MET amplification (17%) and overexpression (50%) and EGFR C797S (15%) are the main mechanisms of acquired resistance to ositinib, consistent
with previous study data.

NKX2.
1 amplification is one of the newly discovered potential mechanisms of
drug resistance.

In the ELIOS study, the efficacy and safety of first-line ositinib was consistent
with the FLAURA study.

Histological data cannot be proactively collected from tissue samples and will be collected retrospectively and analyzed
.

LBA53-ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with First-line (1L) Osimertinib Editor: Small Garden Typesetting: Small Garden Execution: Small Garden

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.